 |
|
|
| |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis:
ONYX-II Post-Treatment Week 24 Results
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Lai Wei1, Gui-Qiang Wang2, Yan Luo3, Chi-Jen Chu4, Seung Woon Paik5, Jinlin Hou6, Jun Cheng7, Qing Xie8, Zhongping Duan9, Jia-Horng Kao10, Bo Fu3, Linda M Fredrick3, Sarah Kopecky-Bromberg3, Niloufar Mobashery3, Jeong Heo11
1Peking University People's Hospital, Beijing, China; 2Peking University First Hospital, Beijing, China; 3AbbVie Inc., North Chicago, Illinois, United States; 4Taipei Veterans General Hospital, Taipei City, Taiwan; 5Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea; 6Nanfang Hospital of Southern Medical University, Guangzhou, China; 7Beijing Di Tan Hospital, Capital Medical University, Beijing, China; 8Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai, China; 9Beijing YouAn Hospital, Capital Medical University, Beijing, China; 10Nati onal Taiwan University Hospital, Zhongzheng District, Taiwan; 11Department of Internal Medicine, College of Medicine, Pusan Nati onal University and Medical Research Institute, Pusan National University Hospital, Busan, Korea (the Republic of)
|
| |
|
|
|
|
|
